Literature DB >> 33353391

The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.

Gin S Malhi1,2,3, Erica Bell1,2,3, Darryl Bassett4, Philip Boyce5,6, Richard Bryant7, Philip Hazell6, Malcolm Hopwood8, Bill Lyndon1, Roger Mulder9, Richard Porter9, Ajeet B Singh10, Greg Murray11.   

Abstract

OBJECTIVES: To provide advice and guidance regarding the management of mood disorders, derived from scientific evidence and supplemented by expert clinical consensus to formulate s that maximise clinical utility.
METHODS: Articles and information sourced from search engines including PubMed, EMBASE, MEDLINE, PsycINFO and Google Scholar were supplemented by literature known to the mood disorders committee (e.g. books, book chapters and government reports) and from published depression and bipolar disorder guidelines. Relevant information was appraised and discussed in detail by members of the mood disorders committee, with a view to formulating and developing consensus-based recommendations and clinical guidance. The guidelines were subjected to rigorous consultation and external review involving: expert and clinical advisors, key stakeholders, professional bodies and specialist groups with interest in mood disorders.
RESULTS: The Royal Australian and New Zealand College of Psychiatrists mood disorders clinical practice guidelines 2020 (MDcpg2020) provide up-to-date guidance regarding the management of mood disorders that is informed by evidence and clinical experience. The guideline is intended for clinical use by psychiatrists, psychologists, primary care physicians and others with an interest in mental health care.
CONCLUSION: The MDcpg2020 builds on the previous 2015 guidelines and maintains its joint focus on both depressive and bipolar disorders. It provides up-to-date recommendations and guidance within an evidence-based framework, supplemented by expert clinical consensus. MOOD DISORDERS COMMITTEE: Gin S Malhi (Chair), Erica Bell, Darryl Bassett, Philip Boyce, Richard Bryant, Philip Hazell, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Richard Porter, Ajeet B Singh and Greg Murray.

Entities:  

Keywords:  Guidelines; bipolar disorder; depression; depressive disorder; management; mania; mood disorders; treatment

Mesh:

Year:  2021        PMID: 33353391     DOI: 10.1177/0004867420979353

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.598


  30 in total

1.  How clinicians can support women in making decisions about psychopharmacological treatments in pregnancy.

Authors:  Megan Galbally; Nicole Woods; Martien Snellen
Journal:  World Psychiatry       Date:  2022-02       Impact factor: 49.548

Review 2.  Short Term Second-Generation Antidepressant Monotherapy in Acute Depressive Episodes of Bipolar II Disorder: A Systematic Review and Meta-Analysis.

Authors:  Jin Hong Park; Nicolas A Nuñez; Manuel Gardea-Resendez; Danielle J Gerberi; Scott Breitinger; Marin Veldic; Mark A Frye; Balwinder Singh
Journal:  Psychopharmacol Bull       Date:  2022-05-31

3.  Social Rhythm Disruption is Associated with Greater Depressive Symptoms in People with Mood Disorders: Findings from a Multinational Online Survey During COVID-19.

Authors:  Piyumi Kahawage; Ben Bullock; Denny Meyer; John Gottlieb; Marie Crowe; Holly A Swartz; Lakshmi N Yatham; Maree Inder; Richard J Porter; Andrew A Nierenberg; Ybe Meesters; Marijke Gordijn; Bartholomeus C M Haarman; Greg Murray
Journal:  Can J Psychiatry       Date:  2022-05-10       Impact factor: 5.321

4.  Complementary medicine in psychology practice: an analysis of Australian psychology guidelines and a comparison with other psychology associations from English speaking countries.

Authors:  Carrie Thomson-Casey; Jon Adams; Erica McIntyre
Journal:  BMC Complement Med Ther       Date:  2022-06-25

Review 5.  Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice.

Authors:  Mohit Chauhan; Rebecca Parry; William V Bobo
Journal:  Neuropsychiatr Dis Treat       Date:  2022-06-14       Impact factor: 2.989

Review 6.  Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.

Authors:  Rebecca L Dean; Tahnee Marquardt; Claudia Hurducas; Styliani Spyridi; Annabelle Barnes; Rebecca Smith; Philip J Cowen; Rupert McShane; Keith Hawton; Gin S Malhi; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2021-10-08

Review 7.  Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention.

Authors:  Erica Bell; Phil Boyce; Richard J Porter; Richard A Bryant; Gin S Malhi
Journal:  CNS Drugs       Date:  2021-05-21       Impact factor: 5.749

8.  Second-generation antidepressants for treatment of seasonal affective disorder.

Authors:  Barbara Nussbaumer-Streit; Kylie Thaler; Andrea Chapman; Thomas Probst; Dietmar Winkler; Andreas Sönnichsen; Bradley N Gaynes; Gerald Gartlehner
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

9.  Understanding Treatment Preferences of Australian Patients Living with Treatment-Resistant Depression.

Authors:  Simon Fifer; Andrea Puig; Vanessa Sequeira; Mustafa Acar; Chee H Ng; Michelle Blanchard; Ariana Cabrera; James Freemantle; Jennifer Grunfeld
Journal:  Patient Prefer Adherence       Date:  2021-07-20       Impact factor: 2.711

Review 10.  Mixed Depression: A Mini-Review to Guide Clinical Practice and Future Research Developments.

Authors:  Antimo Natale; Ludovico Mineo; Laura Fusar-Poli; Andrea Aguglia; Alessandro Rodolico; Massimo Tusconi; Andrea Amerio; Gianluca Serafini; Mario Amore; Eugenio Aguglia
Journal:  Brain Sci       Date:  2022-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.